Veliparib, which was determined to have the lowest PARP-trapping activity, was shown to have a response rate of 47% in patients with platinum-resistant or partially platinum-sensitive BRCA-mutated epithelial ovarian cancer (Vergote et al., 2015). This evidence concerns the gene PARP1 and ovarian carcinoma.